Want to take Stockholm3?
Prostate cancer is the second most common cancer in the world, 1.4 million men are diagnosed yearly. Early detection is the key to successful treatment. Currently, a number of caregivers offer Stockholm3.
-
75000
Participants in clinical studies
-
100 %
More cases of aggressive cancers found
-
50 %
Fewer unnecessary biopsies
-
17-28 %
Reduced healthcare costs
Stockholm3
A3P Biomedical’s lead product is Stockholm3, a blood test that combines protein markers, genetic markers and clinical data with a proprietary algorithm in order to detect aggressive prostate cancer at an early stage.
Press releases
-
A3P Biomedical appoints Anders Martin-Löf as new CFO
May 18, 2022
-
A3P Biomedical has successfully completed a Private Placement of SEK 400 million
May 5, 2022
-
Study published in European Urology Open Science confirms that Stockholm3 provides increased precision in prostate cancer diagnosis
February 28, 2022